By Stephen Karmazyn, BA

Published: January 10, 2017

About the Author

Stephen Karmazyn, BA
Read Full Bio

Advertisement

EnteroMedics Inc: ETRM Stock Soars Again

ETRM StockETRM Stock Shows No Signs of Slowing Down 

EnteroMedics Inc (NASDAQ:ETRM) is yet again on another meteoric rise. ETRM stock ballooned by over 100% last week, and now the stock continues its upward momentum, by rising over 100% by late-afternoon trading on Monday.

The pharmaceutical company is being juiced by some good news regarding its flagship “vBloc” neurometabolic therapy expansion. The continued success of the treatment is the main contributor to ETRM stock’s recent unbelievable streak. (Source: “EnteroMedics (ETRM) Stock: And The Surge Continues,” CNA Finance, January 6, 2017.)

From my previous piece on EnteroMedics, published last week:

Called “vBloc” neurometabolic therapy, EnteroMedics flagship treatment’s expansion announced on Thursday was a huge boon to the company.

Advertisement

This is some much-needed good news for the struggling ETRM stock. Share value has been in steady and steep decline since 2012, dropping from prices in the $4,000 range all the way down to its current price of $4.21. Thursday’s doubling of stock value is a nice change of pace for ETRM stock enthusiasts.

MedStar Health in Maryland and Roper St. Francis in South Carolina added the therapy to their institutions, according to the announcement.

The treatment works to control the sensations of hunger by using a pacemaker-like device that is implanted under the skin. Basically, the device simulates fullness in the patient so it can help them keep away from the fork.

A press release from EnteroMedics Inc explains more about the vBloc treatment:

vBloc Therapy is approved for use in helping with weight loss in people aged 18 years and older who are obese, with a BMI of 40 to 45 kg/m2, or a BMI of 35 to 39.9 kg/m2 with a related health condition such as Type 2 diabetes, high blood pressure, high cholesterol levels or obstructive sleep apnea who have had a poor response to trying to lose weight under supervision in the last 5 years.

(Source: “Commercial Patient Data Confirms Success of EnteroMedics’ vBloc Therapy in Combination with vBloc Achieve Program in Patients Struggling to Lose Weight,” EnteroMedics Inc, December 15, 2016.)

ETRM stock may be one to watch for investors looking to make some quick gains on the back of this stock-burgeoning deal.